登录新浪财经APP 搜索【信披】查看更多考评等级 ● 金宇生物技术股份有限公司（以下简称"公司"）股票于2025年7月15日、7月16日、7月17日连续3个交 易日收盘价格涨幅偏离值累计超过20%。触及《上海证券交易所交易规则》规定的异常波动标准，属于 股票交易异常波动情形。 ● 经公司书面征询本公司第一大股东内蒙古金宇生物控股有限公司（以下简称"生物控股"），截至本公 告披露日，除在指定信息披露媒体及上海证券交易所网站上已公开披露的信息外，不存在应披露而未披 露的信息。 证券代码：600201 证券简称：生物股份 公告编号：临2025-044 金宇生物技术股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 公司于本公告披露日同日披露了《金宇生物技术股份有限公司关于获得兽用生物制品临床试验批件的 公告》，全资子公司金宇保灵生物药品有限公司（以下简称"金宇保灵"）收到农业农村部颁发的非洲猪 瘟亚单位疫苗临床试验批件。兽用生物制品在获得临床试验批准后，需要完成临床试验并申报注册， ...

Core Viewpoint - The city of Hohhot is striving to become the leading hub for veterinary vaccine research and production in China, driven by significant technological breakthroughs and supportive policies in the biopharmaceutical industry [1][3][5] Group 1: Technological Breakthroughs - Jin Yu Bao Ling Biopharmaceutical Co., Ltd. launched the "Jin Niu Zhi" vaccine, marking a major technological advancement in China's biopharmaceutical sector [1] - The company has also established an intelligent manufacturing line capable of producing 8 million doses of pet vaccines annually, which has passed GMP static acceptance [1] - The establishment of the Inner Mongolia Animal Vaccine Technology Innovation Center aims to enhance vaccine research and development, focusing on major animal diseases [2][3] Group 2: Industry Growth and Collaboration - Hohhot has seen its biopharmaceutical industry output grow from 13.11 billion yuan in 2020 to 20.25 billion yuan in 2024, with 117 research institutions and 602 drug registration approvals [4] - The city has actively collaborated with prestigious institutions like the Chinese Academy of Sciences and Tsinghua University to accelerate vaccine development [4] - The introduction of high-value product projects by local companies aims to enhance the quality and innovation of animal serum and vaccine production [2][4] Group 3: Policy Support and Investment - Hohhot has implemented various policies to support the high-quality development of the biopharmaceutical industry, including financial incentives totaling 14 million yuan for innovation platforms and vaccine projects [3] - The city is positioning itself as a national leader in veterinary vaccine production, with significant investments in research and development infrastructure [5] - The establishment of the National Swine Technology Innovation Center in Inner Mongolia signifies the region's commitment to becoming a key player in the animal vaccine industry [4]